Oasmia Pharmaceutical was granted orphan drug designation by the FDA for its drug candidate, Paclical (paclitaxel), for the treatment of ovarian cancer. Oasmia is conducting a Phase 3 study to compare the use of Paclical to Taxol in patients with ovarian cancer.  Paclical is a water soluble formulation of paclitaxel that does not require premedication and without severe Cremophor EL related side effects.

For more information visit www.oasmia.com.